- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05257408
Relacorilant i kombinasjon med Nab-Paclitaxel i avansert, platina-resistent, høygradig epitelial ovarie-, primær peritoneal- eller egglederkreft
En fase 3-studie av relacorilant i kombinasjon med Nab-Paclitaxel versus Nab-Paclitaxel monoterapi i avansert, platina-resistent, høygradig epitelial ovarie-, primær peritoneal- eller egglederkreft (ROSELLA)
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
As there are no currently approved therapies or effective standard of care for heavily pretreated patients with ovarian cancer who have exhausted single-agent chemotherapy and/or bevacizumab, the combination of intermittently administered relacorilant and nab-paclitaxel may demonstrate a substantial improvement without increased toxicity compared with nab-paclitaxel.
Patients will receive study treatment until confirmed progressive disease (PD) or unacceptable toxicity. All patients will be followed for the collection of study endpoints, inclusive of disease progression and survival.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, C1280AEB
- Site 393
-
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina, C1426ANZ
- Site 381
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, X5004FHP
- Site 415
-
Córdoba, Córdoba Province, Argentina, X5008 HHW
- Site 401
-
Córdoba, Córdoba Province, Argentina, X5016
- Site 395
-
-
Mendoza Province
-
Mendoza, Mendoza Province, Argentina, M5500AYB
- Site 404
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, 2000
- Site 391
-
Rosario, Santa Fe Province, Argentina, S2000KDS
- Site 412
-
-
-
-
New South Wales
-
St Leonards, New South Wales, Australia, 2065
- Site 426
-
-
Queensland
-
Benowa, Queensland, Australia, 4217
- Site 417
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Site 414
-
Melbourne, Victoria, Australia, 3128
- Site 419
-
-
-
-
-
Aalst, Belgia, 9300
- Site 328
-
Brussels, Belgia, B- 1200
- Site 109
-
Charleroi, Belgia, 6000
- Site 326
-
Hasselt, Belgia, 3500
- Site 325
-
Leuven, Belgia, 3000
- Site 108
-
Liège, Belgia, B-4000
- Site 327
-
-
-
-
-
Porto Alegre, Brasil, 90035-001
- Site 421
-
-
Brasília - DF
-
Brasília, Brasília - DF, Brasil, 70297-400
- Site 424
-
-
Ceará
-
Fortaleza, Ceará, Brasil, 60170-170
- Site 382
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 41950-640
- Site 384
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30210-040
- Site 383
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasil, 59062-000
- Site 390
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brasil, 22250-905
- Site 380
-
-
São Paulo
-
São Paulo, São Paulo, Brasil, 01321001
- Site 376
-
São Paulo, São Paulo, Brasil, 01327-001
- Site 389
-
São Paulo, São Paulo, Brasil, 01409-002
- Site 413
-
São Paulo, São Paulo, Brasil, 01509-900
- Site 374
-
São Paulo, São Paulo, Brasil, 01509010
- Site 001
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Site 117
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Site 273
-
-
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85016
- Site 318
-
Tucson, Arizona, Forente stater, 85719
- Site 277
-
-
California
-
Irvine, California, Forente stater, 92618
- Site 350
-
La Jolla, California, Forente stater, 92093
- Site 364
-
Palo Alto, California, Forente stater, 94304
- Site 150
-
San Francisco, California, Forente stater, 94109
- Site 278
-
San Francisco, California, Forente stater, 94143
- Site 014
-
Solvang, California, Forente stater, 93463
- Site 316
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Site 032
-
-
Florida
-
Miami Beach, Florida, Forente stater, 33140
- Site 335
-
Weston, Florida, Forente stater, 33331
- Site 042
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Site 009
-
Atlanta, Georgia, Forente stater, 30342
- Site 272
-
Gainesville, Georgia, Forente stater, 30548
- Site 372
-
Savannah, Georgia, Forente stater, 31405
- Site 291
-
-
Illinois
-
Evanston, Illinois, Forente stater, 60201
- Site 315
-
Hinsdale, Illinois, Forente stater, 60521
- Site 314
-
Urbana, Illinois, Forente stater, 61801
- Site 346
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46260
- Site 339
-
-
Kansas
-
Overland Park, Kansas, Forente stater, 66211
- Site 200
-
Overland Park, Kansas, Forente stater, 66211
- Site 334
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40241
- Site 279
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Site 128
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08901
- Site 288
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87131
- Site 292
-
-
New York
-
Flushing, New York, Forente stater, 11355
- Site 275
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45242
- Site 298
-
Cincinnati, Ohio, Forente stater, 45459
- Site 304
-
-
Oregon
-
Portland, Oregon, Forente stater, 97210
- Site 280
-
Portland, Oregon, Forente stater, 97213
- Site 317
-
Portland, Oregon, Forente stater, 97239
- Site 049
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forente stater, 18015
- Site 337
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Site 127
-
-
South Dakota
-
Rapid City, South Dakota, Forente stater, 57701
- Site 276
-
-
Tennessee
-
Germantown, Tennessee, Forente stater, 38138
- Site 368
-
Nashville, Tennessee, Forente stater, 37203
- Site 281
-
-
Texas
-
Austin, Texas, Forente stater, 78731
- Site 229
-
Bedford, Texas, Forente stater, 76022
- Site 312
-
Fort Worth, Texas, Forente stater, 76104
- Site 297
-
San Antonio, Texas, Forente stater, 78240
- Site 392
-
The Woodlands, Texas, Forente stater, 77380
- Site 301
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23502
- Site 300
-
Richmond, Virginia, Forente stater, 23298
- Site 365
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Site 121
-
-
-
-
-
Lille, Frankrike, 59020
- Site 306
-
Montpellier, Frankrike, 34298
- Site 347
-
Nancy, Frankrike, 54100
- Site 307
-
Nice, Frankrike, 06189
- Site 310
-
Paris, Frankrike, 75015
- Site 289
-
Plérin, Frankrike, 22190
- Site 323
-
-
-
-
-
Haifa, Israel, 3436212
- Site 309
-
Jerusalem, Israel, 911201
- Site 080
-
Tel Aviv, Israel, 6423906
- Site 203
-
-
-
-
-
Catania, Italia, 95126
- Site 321
-
Legnago, Italia, 37045
- Site 320
-
Milan, Italia, 20141
- Site 122
-
Pavia, Italia, 27100
- Site 295
-
Roma, Italia, 161
- Site 161
-
Rome, Italia, 00168
- Site 124
-
Torino, Italia, 10128
- Site 293
-
Treviso, Italia, 31100
- Site 319
-
-
-
-
-
Gdynia, Polen, 81-519
- Site 341
-
Poznan, Polen, 61-886
- Site 331
-
Siedlce, Polen, 08-110
- Site 329
-
-
-
-
-
Badalona, Spania, 08916
- Site 349
-
San Sebastián, Spania, 20014
- Site 311
-
Valencia, Spania, 46026
- Site 330
-
-
-
-
-
Cheltenham, Storbritannia, GL53 7AN
- Site 366
-
London, Storbritannia, NW1 2PG
- Site 055
-
Manchester, Storbritannia, M20 4BX
- Site 344
-
Northwood, Storbritannia, HA6 2RN
- Site 345
-
-
East Sussex
-
Brighton, East Sussex, Storbritannia, BN2 1ES
- Site 367
-
-
Somerset
-
Taunton, Somerset, Storbritannia, TA1 5DA
- Site 351
-
-
-
-
-
Gyeonggi-do, Sør -Korea, 10408
- Site 397
-
Seoul, Sør -Korea, 03080
- Site 399
-
Seoul, Sør -Korea, 03722
- Site 398
-
Seoul, Sør -Korea, 05505
- Site 403
-
Seoul, Sør -Korea, 06273
- Site 400
-
Seoul, Sør -Korea, 06351
- Site 396
-
Seoul, Sør -Korea, 08308
- Site 402
-
Seoul, Sør -Korea, 42601
- Site 409
-
-
-
-
-
Budapest, Ungarn, 1122
- Site 322
-
Debrecen, Ungarn, 4032
- Site 290
-
Győr, Ungarn, 9024
- Site 348
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Signed and dated Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to study-specific screening procedures.
- Confirmed histologic diagnosis of high-grade (Grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.
- Patients must have platinum-resistant disease (defined as RECIST v1.1 defined progression <6 months from completion of a platinum-containing therapy).
- Must consent to provide archival tumor-tissue block or slides. Patients may consent to an optional tumor biopsy if archival tumor is unavailable.
- Has a life expectancy of ≥3 months.
- At least one lesion that meets the definition of measurable disease by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Able to comply with protocol requirements.
- Able to swallow and retain oral medication and does not have uncontrolled emesis.
- Received at least 1 but ≤3 lines of prior systemic anticancer therapy and at least 1 prior line of platinum therapy and prior treatment with bevacizumab is required.
- Has adequate organ function meeting the following laboratory-test criteria: Absolute neutrophil count (ANC) ≥1500 cells/mm^3, Platelet count ≥100,000/mm^3, Hemoglobin ≥9 g/dL, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN), or ≤5 × ULN in context of liver metastases, Total bilirubin ≤1.5 × ULN, and Albumin ≥3 g/dL, and creatinine clearance >40 mL/min/1.73 m^2 (measured or estimated).
- Negative pregnancy test for patients of childbearing potential; patients of childbearing potential must agree to use highly effective contraceptive method(s); hormonal contraceptives are not allowed.
- Coronavirus disease (COVID-19) approved vaccines are accepted concomitant medications when recommended by the Investigator.
Exclusion Criteria:
- Has clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that has not resolved to ≤Grade 1 prior to randomization.
- Has had any major surgery within 4 weeks prior to randomization.
- Has low-grade endometrioid, clear cell, mucinous, or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor.
- Has primary platinum-refractory disease, defined as disease that did not respond to or has progressed ≤1 month of the last dose of first-line platinum-containing chemotherapy.
- Has not received prior bevacizumab treatment.
- Has been treated with the following prior to randomization: chemotherapy, immunotherapy, investigational agent treatments for disease under study within 28 days before first dose of study drug, radiotherapy not completed at least 2 weeks prior to first dose of study drug, hormonal anticancer therapies within 7 days of first dose of study drug, and systemic, inhaled, or prescription strength topical corticosteroids within 21 days of first dose of study drug.
- Has received wide-field radiation to more than 25% of marrow-bearing areas.
- Has toxicities of prior therapies that have not resolved by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, ≤Grade 1.
- Requires treatment with chronic or frequently used oral corticosteroids for medical conditions or illnesses.
- Has a history of severe hypersensitivity or severe reaction to any of the study drugs.
- Is receiving concurrent treatment with mifepristone or other glucocorticoid receptor (GR) modulators.
- Has peripheral neuropathy from any cause >Grade 1.
- Pregnant or lactating patients or patients expecting to conceive children within the projected duration of the trial, starting with the screening visit through at least 1 month after the last dose of relacorilant, or 6 months after the last dose of nab-paclitaxel whichever is the longest.
- Has clinically significant uncontrolled condition(s) or condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's safety or participation.
- Has current chronic/active infection with human immunodeficiency virus or current chronic/active infection with hepatitis C virus or hepatitis B virus.
- Has any untreated or symptomatic central nervous system (CNS) metastases.
- Patients with a history of other malignancy within 3 years prior to randomization.
- Is taking a concomitant medication that is a strong cytochrome P450 (CYP)3A inhibitor or strong CYP3A inducer, or that is a substrate of CYP3A with a narrow therapeutic window.
- Concurrent treatment on other investigational treatment studies for the treatment of ovarian, fallopian tube, or primary peritoneal cancer.
- Has received a live vaccine within 30 days prior to the study start date.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2
Patients receive nab-paclitaxel 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle in combination with intermittent relacorilant (150 mg relacorilant once daily on the day before, the day of, and the day after nab-paclitaxel), administered orally under fed conditions. Relacorilant will not be administered on Cycle 1 Day -1. |
Relacorilant is administered as capsules for oral dosing once daily on the day before, the day of, and the day after nab-paclitaxel administration.
Andre navn:
Nab-paclitaxel is administered as intravenous (IV) infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. |
|
Aktiv komparator: Nab-paclitaxel 100 mg/m^2
Patients receive nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle. |
Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
Tidsramme: Up to 20 months
|
PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) or death due to any cause, whichever occurs first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or an unequivocal progression in a non-target lesion, or the appearance of new lesions. |
Up to 20 months
|
|
Overall Survival
Tidsramme: Up to 32 months
|
Overall survival (OS) was assessed as the time from randomization to death by any cause. The data values are Kaplan-Meier estimates. |
Up to 32 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PFS as Assessed by the Investigator
Tidsramme: Up to 20 months
|
PFS was assessed as the time from randomization until the time of first documented progressive disease (PD) by RECIST v1.1, or death due to any cause, whichever occurs first. |
Up to 20 months
|
|
Objective Response as Assessed by the Investigator
Tidsramme: Up to 20 months
|
Objective response was assessed as the proportion of patients with measurable disease at baseline who attained complete response (CR) or partial response (PR). Confirmation of the response was not required for this outcome measure per RECIST v1.1 criteria for randomized controlled clinical trials. Responses were assessed by imaging, using RECIST v1.1 criteria for target lesions: CR, Disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Up to 20 months
|
|
Best Overall Response as Assessed by the Investigator
Tidsramme: Up to 20 months
|
Best overall response was assessed as the proportion of patients with at least 1 post Baseline scan who attained CR, PR, stable disease (SD), or PD as best response by RECIST v1.1. |
Up to 20 months
|
|
Duration of Confirmed Responses as Assessed by the Investigator
Tidsramme: From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
|
The median duration of response is presented for confirmed responses (CR or PR) per RECIST v1.1. Duration of response was from the first documented and confirmed response to the first objectively documented PD as assessed by the Investigator, or death due to any cause, whichever occurs first. |
From the time of confirmed CR or PR to the time of the first PD or death (Up to 18 months)
|
|
Clinical Benefit Rate at 24 Weeks as Assessed by BICR and the Investigator
Tidsramme: 24 weeks
|
Clinical benefit rate was assessed as the proportion of patients who attained CR, PR, or stable disease (SD) for 24 weeks per RECIST v1.1 as assessed by BICR and as assessed by the Investigator. |
24 weeks
|
|
Cancer Antigen (CA)-125 Response
Tidsramme: Up to 24 months
|
CA-125 response was assessed per Gynecologic Cancer Intergroup (GCIG) criteria defined as ≥50% reduction in CA-125 from a pretreatment sample and maintained for ≥28 days in patients with a pretreatment sample that is at least twice the upper limit of the reference range within 2 weeks before starting the treatment. In addition, patients who have a CA-125 response and whose CA-125 level fell to within the reference range were classified as CA-125 complete responders. |
Up to 24 months
|
|
Combined Overall Response Rate by RECIST v1.1 and CA-125 Defined by GCIG Criteria
Tidsramme: Up to 15 months
|
Combined response was assessed as the proportion of patients with tumor response per RECIST v1.1 assessed by the investigator and for CA-125 response per GCIG criteria. |
Up to 15 months
|
|
Number of Patients With One or More Adverse Events
Tidsramme: Up to 22 months
|
Up to 22 months
|
|
|
Number of Patients Who Discontinued the Study Treatment Due to an Adverse Event
Tidsramme: Up to 25 months
|
Up to 25 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Adrian Jubb, MBChB, PhD, FRCPath, Corcept Therapeutics
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study. J Clin Oncol. 2023 Oct 20;41(30):4779-4789. doi: 10.1200/JCO.22.02624. Epub 2023 Jun 26.
- Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balazs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagameri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet. 2025 Jun 21;405(10496):2205-2216. doi: 10.1016/S0140-6736(25)01040-2. Epub 2025 Jun 2.
- Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, Gilbert L, Mileshkin L, Quesada S, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Clamp A, Prillaman C, Diakos C, Bagameri A, Leiser AL, Salutari V, Monk BJ, Follana P, McClung E, Carbone V, Slomovitz B, Giudice E, Cannizzaro MC, Gavoille L, Devaux A, Scollo P, Scandurra G, Cassani C, Artioli G, Van Gorp T, Santaballa A, Dreiling LK, Kesner-Hays A, Tudor IC, Jubb AM, Colombo N, Olawaiye AB. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. Lancet. 2026 Apr 18;407(10538):1513-1524. doi: 10.1016/S0140-6736(26)00462-9. Epub 2026 Apr 10.
- Olawaiye AB, Kim JW, Bagameri A, Bishop E, Chudecka-Glaz A, Devaux A, Gladieff L, Gordinier ME, Korach J, McCollum ME, Mileshkin L, Monk BJ, Nicum S, Nogueira-Rodrigues A, Oaknin A, O'Malley DM, Orlando M, Dreiling L, Tudor IC, Lorusso D. Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer. J Gynecol Oncol. 2024 Jul;35(4):e111. doi: 10.3802/jgo.2024.35.e111.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i det endokrine systemet
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Kjønnssykdommer, kvinner
- Neoplasmer i endokrine kjertel
- Sykdommer i eggstokkene
- Adnexal sykdommer
- Genitale neoplasmer, kvinnelige
- Gonadal lidelser
- Peritoneale sykdommer
- Abdominale neoplasmer
- Eggledersykdommer
- Neoplasmer i eggstokkene
- Peritoneale neoplasmer
- Egglederneoplasmer
- 130-nm albuminbundet paclitaxel
- Relacorilant
Andre studie-ID-numre
- CORT125134-556
- GOG-3073 (Annen identifikator: Gynecologic Oncology Group)
- ROSELLA Study 556 (Annen identifikator: Corcept Therapeutics)
- ENGOT-OV72 (Annen identifikator: European Network of Gynaecological Oncological Trial Groups)
- APGOT-Ov10 (Annen identifikator: Asia-Pacific Gynecologic Oncology Trials Group)
- LACOG 0223 (Annen identifikator: Latin American Cooperative Oncology Group)
- ANZGOG2221/2023 (Annen identifikator: Australia New Zealand Gynaecological Oncology Group)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .